Literature DB >> 14742518

Sensitized splenocytes result in deleterious cytokine cascade and hyperinflammatory response in rats with Pneumocystis pneumonia despite the presence of corticosteroids.

Timothy D Thullen1, Alan D Ashbaugh, Kieran R Daly, Michael J Linke, Paul E Steele, Peter D Walzer.   

Abstract

The immune response to the opportunistic pulmonary pathogen Pneumocystis can have beneficial and harmful effects on the host despite the presence of corticosteroids. We hypothesized that this deleterious hyperinflammatory response is associated with exaggerated cytokine production. The adoptive transfer of at least 10(7) immune splenocytes reduced the cyst count in rats with corticosteroid-induced pneumocystosis. About 18% of these rats developed clinical illness, an increased lung weight/body weight (LW/BW) ratio, and elevated levels of interleukin 1alpha (IL-1alpha), IL-1beta, IL-6, tumor necrosis factor alpha, IL-5, IL-10, and gamma interferon in the lungs. This hyperinflammatory reaction was not observed in rats that remained clinically well or in control rats. Thus, in this model, corticosteroids have little effect on the cytokine cascade or other adverse effects of the host immune response to Pneumocystis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742518      PMCID: PMC321630          DOI: 10.1128/IAI.72.2.757-765.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level.

Authors:  J R Dichter; J D Lundgren; T L Nielsen; B N Jensen; J Schattenkerk; T L Benfield; M Lawrence; J Shelhamer
Journal:  Respir Med       Date:  1999-06       Impact factor: 3.415

Review 2.  Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention.

Authors:  W T Hughes
Journal:  Pediatr Infect Dis J       Date:  1991-05       Impact factor: 2.129

3.  Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome.

Authors: 
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

4.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumonia.

Authors:  T L Benfield; J K Schattenkerk; B Hofmann; B N Jensen; T L Nielsen; J D Lundgren
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

6.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia.

Authors:  T L Benfield; J Vestbo; J Junge; T L Nielsen; A B Jensen; J D Lundgren
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

8.  Effect of corticosteroids on IL1 beta and TNF alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia.

Authors:  Z B Huang; E Eden
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

9.  Production of tumor necrosis factor-alpha by blood and lung mononuclear phagocytes from patients with human immunodeficiency virus-related lung disease.

Authors:  A B Millar; R F Miller; N M Foley; A Meager; S J Semple; G A Rook
Journal:  Am J Respir Cell Mol Biol       Date:  1991-08       Impact factor: 6.914

10.  Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats.

Authors:  D M Schmatz; M A Powles; D C McFadden; L Pittarelli; J Balkovec; M Hammond; R Zambias; P Liberator; J Anderson
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.